SLCO4C1 and chronic kidney disease: OATP4C1 mediates the cellular uptake of asymmetric dimethylarginine (ADMA), a uremic toxin known to contribute to endothelial dysfunction and CVD development in patients with CKD [137,138,139,140,141].